BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/27/2018 8:56:32 AM | Browse: 935 | Download: 1360
 |
Received |
|
2018-09-28 01:51 |
 |
Peer-Review Started |
|
2018-09-28 09:07 |
 |
To Make the First Decision |
|
2018-10-17 01:03 |
 |
Return for Revision |
|
2018-10-23 02:06 |
 |
Revised |
|
2018-10-27 11:38 |
 |
Second Decision |
|
2018-11-07 09:20 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2018-11-08 02:24 |
 |
Articles in Press |
|
2018-11-08 02:24 |
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2018-12-26 02:42 |
 |
Publish the Manuscript Online |
|
2018-12-27 08:56 |
ISSN |
1007-9327 (print) and 2219-2840 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
Category |
Gastroenterology & Hepatology |
Manuscript Type |
Editorial |
Article Title |
Role of cenicriviroc in the management of nonalcoholic fatty liver disease
|
Manuscript Source |
Invited Manuscript |
All Author List |
Georgios Neokosmidis and Konstantinos Tziomalos |
ORCID |
|
Funding Agency and Grant Number |
|
Corresponding Author |
Konstantinos Tziomalos, MD, MSc, PhD, Assistant Professor, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 1 Stilponos Kyriakidi Street, Thessaloniki 54636, Greece. ktziomal@auth.gr |
Key Words |
Cenicriviroc; Macrophages; Nonalcoholic fatty liver disease; Fibrosis; Nonalcoholic steatohepatitis |
Core Tip |
Macrophages appear to play an important role in the development and progression of hepatic fibrosis in patients with nonalcoholic fatty liver disease (NAFLD). Accordingly, modulation of macrophage trafficking might represent an attractive therapeutic strategy in this population. Cenicriviroc is an oral inhibitor of the chemokine ligand 2/C-C chemokine receptor 2 pathway, which plays an important role in the hepatic recruitment of the macrophages. Preclinical studies and a phase 2b study in humans suggest that this agent might hold promise in the management of NAFLD. |
Publish Date |
2018-12-27 08:56 |
Citation |
Neokosmidis G, Tziomalos K. Role of cenicriviroc in the management of nonalcoholic fatty liver disease. World J Gastroenterol 2018; 24(48): 5415-5417 |
URL |
https://www.wjgnet.com/1007-9327/full/v24/i48/5415.htm |
DOI |
https://dx.doi.org/10.3748/wjg.v24.i48.5415 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345